TissueGen representatives will be at the show to discuss how ELUTE fiber’s manufacturing process enables controlled sustained delivery of the broadest range of temperature-sensitive pharmaceuticals and biologics through biodegradable fiber-based devices.
TissueGen will present how ELUTE fiber enables medical device developers to achieve breakthroughs across a broad range of medical applications at MD&M East 2016. TissueGen enables controlled sustained delivery of sensitive pharmaceuticals and biologics from biodegradable fibers for advanced drug delivery, nerve regeneration and tissue engineering.
TissueGen representatives will be at the show to discuss how ELUTE fiber’s patented manufacturing process enables controlled sustained delivery of the broadest range of temperature-sensitive pharmaceuticals and biologics through biodegradable fiber-based devices.
ELUTE fiber is developed and manufactured in an ISO Class 7 clean room facility to support compliance with FDA cGMP requirements for manufacturing drug product. Earlier this year TissueGen was awarded ISO13485:2003 certification following significant investment in its quality management system and upgrades to its research, development and production infrastructure.
TissueGen
www.tissuegen.com
